Rapid and simultaneous identification of three mutations by the Novaplex™ SARS-CoV-2 variants I assay kit

•Important mutations in nasal swab samples simultaneously detected.•Easy to use and cost-effective PCR-based kit was used for identifying the mutations.•Whole-genome sequencing and mapping to reference genome revealed a novel variant.•Variant with exclusive E484K substitution identified in two sampl...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical virology 2021-08, Vol.141, p.104877-104877, Article 104877
Hauptverfasser: Kami, Wakaki, Kinjo, Takeshi, Arakaki, Wakako, Oki, Hiroya, Motooka, Daisuke, Nakamura, Shota, Fujita, Jiro
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 104877
container_issue
container_start_page 104877
container_title Journal of clinical virology
container_volume 141
creator Kami, Wakaki
Kinjo, Takeshi
Arakaki, Wakako
Oki, Hiroya
Motooka, Daisuke
Nakamura, Shota
Fujita, Jiro
description •Important mutations in nasal swab samples simultaneously detected.•Easy to use and cost-effective PCR-based kit was used for identifying the mutations.•Whole-genome sequencing and mapping to reference genome revealed a novel variant.•Variant with exclusive E484K substitution identified in two samples.•Turnaround time of the kit-based assay was only 2 h. . The emergence of SARS-CoV-2 variants has caused an unexpected rebound globally. The World Health Organization has listed three variants (B.1.1.7, B.1.351, and P.1) as variants of concern. To understand the epidemiology and thereby plan appropriate safety measures, differential identification of the variants is indeed critical. . Although whole-genome sequencing is the gold standard for variant identification, it is time-consuming and relatively expensive. Therefore, a rapid, easy, and cost-effective platform targeting multiple regions of the genome is required. Here, we assessed the usefulness of the Novaplex™ SARS-CoV-2 Variants I Assay kit in identifying mutations in the variants. . We retrospectively examined 30 stored nasal swabs from COVID-19-positive patients tested between November 2020 and March 2021. RNA extracted from these swabs was subjected to the commercial kit and real-time reverse transcription-PCR was performed. To determine the genome sequences of SARS-CoV-2 in the collected samples and deduce the consensus sequences among the identified variants, genome sequencing libraries were prepared and mapped to the reference genome. . Four of the tested samples were determined as variants. Of them, two harbored both H69/V70 deletion and N501Y substitution, whereas two harbored E484K substitution alone. . The variant with E484K substitution alone (“R.1”) has been now categorized as a variant of interest in Japan. Additionally, the kit-based assay was found to be feasible, convenient, and user-friendly in identifying the abovementioned mutations with a turnaround time of only 2 h.
doi_str_mv 10.1016/j.jcv.2021.104877
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8164504</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S138665322100144X</els_id><sourcerecordid>2542360846</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3667-27033ab94565167d888a7dfdca38d79c9019e8e0845ea6dbac175b932c8c8ad93</originalsourceid><addsrcrecordid>eNp9kc9u1DAQxiMEoqXwAFyQj1yy2LFjO0JCqlb8qVSB1AJXa2JPqLdJvNhJxN55Eh6NJ8ElpYILJ49nvvk8nl9RPGV0wyiTL3abnV02Fa1Yvgut1L3imGnFy7qR6n6OuZalrHl1VDxKaUcpq7lQD4sjLhgXlIvj4voC9t4RGB1Jfpj7CUYMcyLe4Tj5zluYfBhJ6Mh0FRHJME-_M4m0h5xC8j4ssO_x28_vP8jl6cVluQ2fy4osED2MUyJnBFKCA7n20-PiQQd9wie350nx6c3rj9t35fmHt2fb0_PScilVWSnKObSNqGXNpHJaa1Cucxa4dqqxDWUNaqRa1AjStWCZqtuGV1ZbDa7hJ8Wr1Xc_twM6m38SoTf76AeIBxPAm38ro78yX8JiNJOipiIbPL81iOHrjGkyg08W-35djqlqUXGZB5BZylapjSGliN3dM4yaG0hmZzIkcwPJrJByz7O_57vr-EMlC16uAsxbWjxGk6zH0aLzEe1kXPD_sf8Fucykhw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2542360846</pqid></control><display><type>article</type><title>Rapid and simultaneous identification of three mutations by the Novaplex™ SARS-CoV-2 variants I assay kit</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Kami, Wakaki ; Kinjo, Takeshi ; Arakaki, Wakako ; Oki, Hiroya ; Motooka, Daisuke ; Nakamura, Shota ; Fujita, Jiro</creator><creatorcontrib>Kami, Wakaki ; Kinjo, Takeshi ; Arakaki, Wakako ; Oki, Hiroya ; Motooka, Daisuke ; Nakamura, Shota ; Fujita, Jiro</creatorcontrib><description>•Important mutations in nasal swab samples simultaneously detected.•Easy to use and cost-effective PCR-based kit was used for identifying the mutations.•Whole-genome sequencing and mapping to reference genome revealed a novel variant.•Variant with exclusive E484K substitution identified in two samples.•Turnaround time of the kit-based assay was only 2 h. . The emergence of SARS-CoV-2 variants has caused an unexpected rebound globally. The World Health Organization has listed three variants (B.1.1.7, B.1.351, and P.1) as variants of concern. To understand the epidemiology and thereby plan appropriate safety measures, differential identification of the variants is indeed critical. . Although whole-genome sequencing is the gold standard for variant identification, it is time-consuming and relatively expensive. Therefore, a rapid, easy, and cost-effective platform targeting multiple regions of the genome is required. Here, we assessed the usefulness of the Novaplex™ SARS-CoV-2 Variants I Assay kit in identifying mutations in the variants. . We retrospectively examined 30 stored nasal swabs from COVID-19-positive patients tested between November 2020 and March 2021. RNA extracted from these swabs was subjected to the commercial kit and real-time reverse transcription-PCR was performed. To determine the genome sequences of SARS-CoV-2 in the collected samples and deduce the consensus sequences among the identified variants, genome sequencing libraries were prepared and mapped to the reference genome. . Four of the tested samples were determined as variants. Of them, two harbored both H69/V70 deletion and N501Y substitution, whereas two harbored E484K substitution alone. . The variant with E484K substitution alone (“R.1”) has been now categorized as a variant of interest in Japan. Additionally, the kit-based assay was found to be feasible, convenient, and user-friendly in identifying the abovementioned mutations with a turnaround time of only 2 h.</description><identifier>ISSN: 1386-6532</identifier><identifier>EISSN: 1873-5967</identifier><identifier>DOI: 10.1016/j.jcv.2021.104877</identifier><identifier>PMID: 34134034</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>COVID-19 ; Humans ; Mutation ; Mutations ; Retrospective Studies ; SARS-CoV-2 ; Short Communication ; Spike Glycoprotein, Coronavirus - genetics ; Variant ; Whole-genome sequencing</subject><ispartof>Journal of clinical virology, 2021-08, Vol.141, p.104877-104877, Article 104877</ispartof><rights>2021</rights><rights>Copyright © 2021. Published by Elsevier B.V.</rights><rights>2021 Elsevier B.V. All rights reserved. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3667-27033ab94565167d888a7dfdca38d79c9019e8e0845ea6dbac175b932c8c8ad93</citedby><cites>FETCH-LOGICAL-c3667-27033ab94565167d888a7dfdca38d79c9019e8e0845ea6dbac175b932c8c8ad93</cites><orcidid>0000-0003-3423-8343 ; 0000-0003-2058-5942 ; 0000-0002-0885-5375 ; 0000-0002-3679-1284</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S138665322100144X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34134034$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kami, Wakaki</creatorcontrib><creatorcontrib>Kinjo, Takeshi</creatorcontrib><creatorcontrib>Arakaki, Wakako</creatorcontrib><creatorcontrib>Oki, Hiroya</creatorcontrib><creatorcontrib>Motooka, Daisuke</creatorcontrib><creatorcontrib>Nakamura, Shota</creatorcontrib><creatorcontrib>Fujita, Jiro</creatorcontrib><title>Rapid and simultaneous identification of three mutations by the Novaplex™ SARS-CoV-2 variants I assay kit</title><title>Journal of clinical virology</title><addtitle>J Clin Virol</addtitle><description>•Important mutations in nasal swab samples simultaneously detected.•Easy to use and cost-effective PCR-based kit was used for identifying the mutations.•Whole-genome sequencing and mapping to reference genome revealed a novel variant.•Variant with exclusive E484K substitution identified in two samples.•Turnaround time of the kit-based assay was only 2 h. . The emergence of SARS-CoV-2 variants has caused an unexpected rebound globally. The World Health Organization has listed three variants (B.1.1.7, B.1.351, and P.1) as variants of concern. To understand the epidemiology and thereby plan appropriate safety measures, differential identification of the variants is indeed critical. . Although whole-genome sequencing is the gold standard for variant identification, it is time-consuming and relatively expensive. Therefore, a rapid, easy, and cost-effective platform targeting multiple regions of the genome is required. Here, we assessed the usefulness of the Novaplex™ SARS-CoV-2 Variants I Assay kit in identifying mutations in the variants. . We retrospectively examined 30 stored nasal swabs from COVID-19-positive patients tested between November 2020 and March 2021. RNA extracted from these swabs was subjected to the commercial kit and real-time reverse transcription-PCR was performed. To determine the genome sequences of SARS-CoV-2 in the collected samples and deduce the consensus sequences among the identified variants, genome sequencing libraries were prepared and mapped to the reference genome. . Four of the tested samples were determined as variants. Of them, two harbored both H69/V70 deletion and N501Y substitution, whereas two harbored E484K substitution alone. . The variant with E484K substitution alone (“R.1”) has been now categorized as a variant of interest in Japan. Additionally, the kit-based assay was found to be feasible, convenient, and user-friendly in identifying the abovementioned mutations with a turnaround time of only 2 h.</description><subject>COVID-19</subject><subject>Humans</subject><subject>Mutation</subject><subject>Mutations</subject><subject>Retrospective Studies</subject><subject>SARS-CoV-2</subject><subject>Short Communication</subject><subject>Spike Glycoprotein, Coronavirus - genetics</subject><subject>Variant</subject><subject>Whole-genome sequencing</subject><issn>1386-6532</issn><issn>1873-5967</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc9u1DAQxiMEoqXwAFyQj1yy2LFjO0JCqlb8qVSB1AJXa2JPqLdJvNhJxN55Eh6NJ8ElpYILJ49nvvk8nl9RPGV0wyiTL3abnV02Fa1Yvgut1L3imGnFy7qR6n6OuZalrHl1VDxKaUcpq7lQD4sjLhgXlIvj4voC9t4RGB1Jfpj7CUYMcyLe4Tj5zluYfBhJ6Mh0FRHJME-_M4m0h5xC8j4ssO_x28_vP8jl6cVluQ2fy4osED2MUyJnBFKCA7n20-PiQQd9wie350nx6c3rj9t35fmHt2fb0_PScilVWSnKObSNqGXNpHJaa1Cucxa4dqqxDWUNaqRa1AjStWCZqtuGV1ZbDa7hJ8Wr1Xc_twM6m38SoTf76AeIBxPAm38ro78yX8JiNJOipiIbPL81iOHrjGkyg08W-35djqlqUXGZB5BZylapjSGliN3dM4yaG0hmZzIkcwPJrJByz7O_57vr-EMlC16uAsxbWjxGk6zH0aLzEe1kXPD_sf8Fucykhw</recordid><startdate>20210801</startdate><enddate>20210801</enddate><creator>Kami, Wakaki</creator><creator>Kinjo, Takeshi</creator><creator>Arakaki, Wakako</creator><creator>Oki, Hiroya</creator><creator>Motooka, Daisuke</creator><creator>Nakamura, Shota</creator><creator>Fujita, Jiro</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-3423-8343</orcidid><orcidid>https://orcid.org/0000-0003-2058-5942</orcidid><orcidid>https://orcid.org/0000-0002-0885-5375</orcidid><orcidid>https://orcid.org/0000-0002-3679-1284</orcidid></search><sort><creationdate>20210801</creationdate><title>Rapid and simultaneous identification of three mutations by the Novaplex™ SARS-CoV-2 variants I assay kit</title><author>Kami, Wakaki ; Kinjo, Takeshi ; Arakaki, Wakako ; Oki, Hiroya ; Motooka, Daisuke ; Nakamura, Shota ; Fujita, Jiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3667-27033ab94565167d888a7dfdca38d79c9019e8e0845ea6dbac175b932c8c8ad93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>COVID-19</topic><topic>Humans</topic><topic>Mutation</topic><topic>Mutations</topic><topic>Retrospective Studies</topic><topic>SARS-CoV-2</topic><topic>Short Communication</topic><topic>Spike Glycoprotein, Coronavirus - genetics</topic><topic>Variant</topic><topic>Whole-genome sequencing</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kami, Wakaki</creatorcontrib><creatorcontrib>Kinjo, Takeshi</creatorcontrib><creatorcontrib>Arakaki, Wakako</creatorcontrib><creatorcontrib>Oki, Hiroya</creatorcontrib><creatorcontrib>Motooka, Daisuke</creatorcontrib><creatorcontrib>Nakamura, Shota</creatorcontrib><creatorcontrib>Fujita, Jiro</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kami, Wakaki</au><au>Kinjo, Takeshi</au><au>Arakaki, Wakako</au><au>Oki, Hiroya</au><au>Motooka, Daisuke</au><au>Nakamura, Shota</au><au>Fujita, Jiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rapid and simultaneous identification of three mutations by the Novaplex™ SARS-CoV-2 variants I assay kit</atitle><jtitle>Journal of clinical virology</jtitle><addtitle>J Clin Virol</addtitle><date>2021-08-01</date><risdate>2021</risdate><volume>141</volume><spage>104877</spage><epage>104877</epage><pages>104877-104877</pages><artnum>104877</artnum><issn>1386-6532</issn><eissn>1873-5967</eissn><abstract>•Important mutations in nasal swab samples simultaneously detected.•Easy to use and cost-effective PCR-based kit was used for identifying the mutations.•Whole-genome sequencing and mapping to reference genome revealed a novel variant.•Variant with exclusive E484K substitution identified in two samples.•Turnaround time of the kit-based assay was only 2 h. . The emergence of SARS-CoV-2 variants has caused an unexpected rebound globally. The World Health Organization has listed three variants (B.1.1.7, B.1.351, and P.1) as variants of concern. To understand the epidemiology and thereby plan appropriate safety measures, differential identification of the variants is indeed critical. . Although whole-genome sequencing is the gold standard for variant identification, it is time-consuming and relatively expensive. Therefore, a rapid, easy, and cost-effective platform targeting multiple regions of the genome is required. Here, we assessed the usefulness of the Novaplex™ SARS-CoV-2 Variants I Assay kit in identifying mutations in the variants. . We retrospectively examined 30 stored nasal swabs from COVID-19-positive patients tested between November 2020 and March 2021. RNA extracted from these swabs was subjected to the commercial kit and real-time reverse transcription-PCR was performed. To determine the genome sequences of SARS-CoV-2 in the collected samples and deduce the consensus sequences among the identified variants, genome sequencing libraries were prepared and mapped to the reference genome. . Four of the tested samples were determined as variants. Of them, two harbored both H69/V70 deletion and N501Y substitution, whereas two harbored E484K substitution alone. . The variant with E484K substitution alone (“R.1”) has been now categorized as a variant of interest in Japan. Additionally, the kit-based assay was found to be feasible, convenient, and user-friendly in identifying the abovementioned mutations with a turnaround time of only 2 h.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>34134034</pmid><doi>10.1016/j.jcv.2021.104877</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-3423-8343</orcidid><orcidid>https://orcid.org/0000-0003-2058-5942</orcidid><orcidid>https://orcid.org/0000-0002-0885-5375</orcidid><orcidid>https://orcid.org/0000-0002-3679-1284</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1386-6532
ispartof Journal of clinical virology, 2021-08, Vol.141, p.104877-104877, Article 104877
issn 1386-6532
1873-5967
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8164504
source MEDLINE; Elsevier ScienceDirect Journals
subjects COVID-19
Humans
Mutation
Mutations
Retrospective Studies
SARS-CoV-2
Short Communication
Spike Glycoprotein, Coronavirus - genetics
Variant
Whole-genome sequencing
title Rapid and simultaneous identification of three mutations by the Novaplex™ SARS-CoV-2 variants I assay kit
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T11%3A06%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rapid%20and%20simultaneous%20identification%20of%20three%20mutations%20by%20the%20Novaplex%E2%84%A2%20SARS-CoV-2%20variants%20I%20assay%20kit&rft.jtitle=Journal%20of%20clinical%20virology&rft.au=Kami,%20Wakaki&rft.date=2021-08-01&rft.volume=141&rft.spage=104877&rft.epage=104877&rft.pages=104877-104877&rft.artnum=104877&rft.issn=1386-6532&rft.eissn=1873-5967&rft_id=info:doi/10.1016/j.jcv.2021.104877&rft_dat=%3Cproquest_pubme%3E2542360846%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2542360846&rft_id=info:pmid/34134034&rft_els_id=S138665322100144X&rfr_iscdi=true